Related Experiment Video
Updated: Jun 12, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
Upadacitinib in refractory cutaneous pseudolymphoma: A case report
Elisabetta Danese1, Tea Curic1, Francesco Bellinato1
1Section of Dermatology and Venereology, Department of Medicine, University of Verona, Italy.
Abstract:
Cutaneous pseudolymphoma is a benign condition characterized by a reactive B-cell, T-cell or mixed lymphoproliferative process. Different causative agents (e.g. injected substances, tattoo, drugs and insect bites) have been described, but in many cases no cause can be identified; hence, the term idiopathic cutaneous pseudolymphoma. There are no specific guidelines for the treatment of cutaneous pseudolymphoma, and sometimes a few cases are refractory to conventional treatments. We describe a case of a 41-year-old African woman with refractory facial IgG4 pseudolymphoma successfully treated with upadacitinib.
Related Concept Videos
Drug Discovery: Overview
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...

